Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128680 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
A Phase 1 study of Stage IV Renal Cell Cancer AJCC v8 and Stage III Renal Cell Cancer AJCC v8, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 2
- Study locations
NCT07128680 is a Phase 1 study of Stage IV Renal Cell Cancer AJCC v8 and Stage III Renal Cell Cancer AJCC v8 that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 33 participants, below the 151-participant average among 24 other Stage IV Renal Cell Cancer AJCC v8 trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07128680, a Phase 1 study of Stage IV Renal Cell Cancer AJCC v8 and Stage III Renal Cell Cancer AJCC v8, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial tests the safety and effectiveness of nivolumab and ipilimumab with and without EXL01 for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. EXL01 is a live biotherapeutic product containing a strain of bacteria called Faecalibacterium prausnitzii. It may enhance a patient's response to treatment with immune checkpoint inhibitors like nivolumab and ipilimumab by altering the composition of the bacteria in the gut. Adding EXL01 to treatment with nivolumab and ipilimumab may be safe and more effective than giving nivolumab and ipilimumab alone.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Bone Scan
- BIOLOGICAL Ipilimumab
- DIETARY_SUPPLEMENT Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01
Study Locations (2)
California
- City of Hope Medical Center - Duarte
- City of Hope Medical Center - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2028-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07128680
The ClinicalTrials.gov registry entry for NCT07128680 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 24 other Stage IV Renal Cell Cancer AJCC v8 trials with a reported enrollment target (78% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Stage IV Renal Cell Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07128680 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07128680 about?
NCT07128680 is a clinical study titled "Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer". This phase I trial tests the safety and effectiveness of nivolumab and ipilimumab with and without EXL01 for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivol...
What is the current status of trial NCT07128680?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2026-04-01. Estimated completion is 2028-08-25.
What conditions does trial NCT07128680 study?
This clinical trial studies the following conditions: Stage IV Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma.
What interventions are being tested in trial NCT07128680?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Bone Scan (PROCEDURE), Ipilimumab (BIOLOGICAL), Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07128680?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128680 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Renal Cell Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
RECRUITING · Phase 1
-
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
RECRUITING · Phase 1
-
Imaging of Solid Tumors Using 18F-TRX
RECRUITING · Phase 1
-
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
ACTIVE NOT RECRUITING · Phase 1
-
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Stage IV Renal Cell Cancer AJCC v8
All registered trials for this condition
Stage III Renal Cell Cancer AJCC v8
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.